EBC & EFPIA launch RETHINKING Alzheimer’s disease White Paper
About Alzheimer’s disease
Alzheimer’s disease (AD), the most common form of dementia, is a progressive and debilitating neurodegenerative condition which robs people of their memory, their independence, their relationships and, ultimately, their lives. It affects close to 7 million people in the European Union (EU) alone. AD is a growing public health issue with a huge burden for European economies, national healthcare and social care systems and a concern for the future.
Rethinking the detection and diagnosis of Alzheimer’s
Scaling-up health systems readiness
In addition, and in light of emerging detection and diagnosis modalities, as well as disease-modifying treatments (DMTs), more research on how biomarkers should be used for diagnosing AD in a clinical setting should be considered. Disclosing biomarkers results and related risk to people living with AD should also be improved.
Lastly, instruments to enhance access to early diagnosis are patient registries and databases as well as national dementia plans. The former are key elements to better understand the disease and develop clinical research. They also improve the lives of people living with AD and their healthcare planning. The latter must be developed in concertation with all stakeholders to ensure they cover all priorities, including awareness raising, education, flexibility to take stock of innovation and dedicated funding for implementation.
The policy recommendations gathered in this White Paper provide solid directions on how to rethink the detection and diagnosis of AD to help overcome the current challenges and be prepared to embrace innovation.
Read more about the Rethinking Alzheimer’s Disease project here.
Read the white paper here.